Coblopasvir
Cat. No.：YN252027
| 产品名称: | Coblopasvir |
| CAS No.: | 1312608-46-0 |
| Chemical Name: | N-[(1S)-1-[[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-carbamic acid, methyl ester |
| Synonyms: | KW-136 |
| 分子量: | 782.88482 |
| 分子式: | C41H50N8O8 |
| SMILES: | O=C([C@H](C(C)C)NC(OC)=O)N1CCC[C@@]1([H])C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@]6([H])CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C7=C4OCO7)C=C3)N2 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Coblopasvir (KW-136) 是泛基因型非结构蛋白5A(NS5A)抑制剂。Coblopasvir 可用于慢性丙型肝炎病毒感染的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Rao, H., Song, G., Li, G., et al.Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosisJ. Viral. Hepat.27(1),45-51(2020)
